Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

OBJECTIVES: Clinical trials of tumour necrosis factor antagonists have raised questions about the potential risk of certain serious adverse events (SAE). To assess the safety of adalimumab in rheumatoid arthritis (RA) over time and across five other immune-mediated inflammatory diseases and to compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, G R, Mease, P, Dijkmans, B A C, Gordon, K, Lovell, D, Panaccione, R, Perez, J, Pangan, A L
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2009
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770105/
https://www.ncbi.nlm.nih.gov/pubmed/19147611
http://dx.doi.org/10.1136/ard.2008.102103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770105/
https://www.ncbi.nlm.nih.gov/pubmed/19147611
http://dx.doi.org/10.1136/ard.2008.102103

Ejemplares similares